% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • jwrye jwrye Dec 2, 2010 11:10 AM Flag

    Intresting XL 184 reduces bone degeneration

    IMO good news but not blockbuster results based on positive results for less than half in all types of cancers.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • To me it seems there is a market for it in all advanced prostrate cancer patients suffering from pain.Even if it is not the answer for stopping prostrate cancer;it can eliminate the need for narcotics.That in it self it a major advange to the suffers.

      • 1 Reply to clemcaldwell
      • All you need to do is look at the huge bisphonate market that has been created to treat bone metastases associated with cancers such as breast, prostate, and multiple myeloma. Many major cancers can be managed but all of these mentioned eventually have mets that move out to the bone areas. XL 184 addresses a major unmet need in a major market. Remember, prostate cancer is the most common, non-skin (melanoma) cancer in men. Huge potential. This drug alone in prostate may be enough to get other companies interested. These are UNPRECEDENTED RESULTS. While it is early and the trial is small, no other drug has come close to these results. And this does not even consider the role of XL 184 in tumors such as ovarian cancer.

9.18+0.23(+2.57%)Jul 29 4:00 PMEDT